References
- NIH. Information for Researchers: Coronaviruses. National Institute of Allergy and Infectious Disease. Available from: https://www.niaid.nih.gov/diseases-conditions/coronaviruses. Accessed April 15, 2021.
- Morens DM, Breman JG, Calisher CH, et al. The Origin of COVID-19 and why it matters. Am J Trop Med Hyg. 2020;103:955–959.
- Bolsen T, Palm R, Kingsland JT. Framing the origins of COVID-19. Sci Commun. 2020;1075547020953603.
- Jih TK. Acute respiratory distress syndrome (ARDS) and severe acute respiratory syndrome (SARS): are we speaking different languages? J Chin Med Assoc. 2005;68:1–3.
- Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care. 2020;24:198.
- Chang JC. Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clin Appl Thromb Hemost. 2019;25:1076029619887437.
- Romagnoli S, Peris A, De Gaudio AR, et al. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev. 2020;100(4):1455–1466.
- Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448.
- Fletcher-Sandersjöö A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res. 2020;194:36–41.
- Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024
- Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J. 2020;56:2001365.
- Schultz K, Wolf JM. Digital ischemia in COVID-19 patients: case report. J Hand Surg Am. 2020;45:518–522.
- Kanitakis J, Lesort C, Danset M, et al. Chilblain-like acral lesions during the COVID-19 pandemic (“COVID toes”): histologic, immunofluorescence, and immunohistochemical study of 17 cases. J Am Acad Dermatol. 2020;83:870–875.
- Pourdowlat G, Naderi Z, et al. Acrocyanosis and digital necrosis are associated with poor prognosis in COVID-19. Clin Case Rep. 2020;8:2769–2772.
- de Nooijer AH, Grondman I, Janssen NAF, et al. Complement activation in the disease course of COVID-19 and its effects on clinical outcomes. J Infect Dis. 2021;223:214–224.
- Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
- Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146:215–217.
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–128.
- Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575–e582.
- Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136:489–500.
- Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738–1742.
- Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J. 2019;17:10.
- Chang JC. Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis. Thrombosis J. 2020;18:25.
- Bernardo A, Ball C, Nolasco L, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3:562–570.
- Ali A, Vijayan R. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Sci Rep. 2020;10:14214.
- Farkas I, Baranyi L, Ishikawa Y, et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J Physiol. 2002;539(Pt 2):537–545.
- Kumar A, Narayan RK, Kumari C, et al. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Med Hypotheses. 2020;145:110320.
- Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J. 2018;16:20.
- Capecchi M, Mocellin C, Abbruzzese C, Mancini I, Prati D, Peyvandi F. Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19. Haematologica. 2020;105:e540.
- Hindilerden F, Yonal-Hindilerden I, Akar E, et al. Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case. Thromb Res. 2020;195:136–138.
- Jhaveri KD, Meir LR, Flores chang BS, et al. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020;98:509–512.
- Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020;189:e227–e30.
- Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–109.
- Kroll MH, Afshar-Kharghan V. Platelets in pulmonary vascular physiology and pathology. Pulm Circ. 2012;2:291–308.
- Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine. 2020;24:100434.
- Chemla D, Castelain V, Provencher S, et al. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest. 2009;135:760–768.
- Kamran SM, Mirza ZE, Naseem A, et al. plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study. PLoS One. 2021;16:e0244853.
- Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45:100618.
- Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091.
- Robba C, Battaglini D, Pelosi P, et al. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med. 2020;14:865–868.
- Wang L, Zhang Y, Zhang S. Cardiovascular impairment in COVID-19: learning from current options for cardiovascular anti-inflammatory therapy. Front Cardiovasc Med. 2020;7:78.
- Elsoukkary SS, Mostyka M, Dillard A, et al. Autopsy findings in 32 patients with COVID-19: a single-institution experience. Pathobiology. 2021;88:56–68.
- Mokhtari T, Hassani F, Ghaffari N, et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Histol. 2020;51:613–628.
- Wang J, Jiang M, Chen X, et al. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17–41.
- Simpson JM, Newburger JW. Multisystem inflammatory syndrome in children in association with COVID-19. Circulation. 2020;142:437–440.
- Ortega-Paz L, Capodanno D, Montalescot G, et al. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10:e019650.
- Mondal S, Quintili AL, Karamchandani K, et al. Thromboembolic disease in COVID-19 patients: a brief narrative review. J Intensive Care. 2020;8:70.
- Hajra A, Mathai SV, Ball S, et al. Management of thrombotic complications in COVID-19: an update. Drugs. 2020;80:1553–1562.
- Zhang R, Ni L, Di X, et al. Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients. J Vasc Surg Venous Lymphat Disord. 2021;9:289–298.e5).
- Boonyawat K, Chantrathammachart P, Numthavaj P, et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thrombosis J. 2020;18:34.
- Merrill JT, Erkan D, Winakur J, et al. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16:581–589.
- Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268–277.
- Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020;173:350–361.
- Bois MC, Boire NA, Layman AJ, et al. COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation. 2021;143:230–243.
- Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18:1548–1555.
- Chang JC. Stroke classification: critical role of unusually large von willebrand factor multimers and tissue factor on clinical phenotypes based on novel “two-path unifying theory” of hemostasis. Clin Appl Thromb Hemost. 2020;26:1076029620913634.
- Chang JC. Thrombogenesis and thrombotic disorders based on ‘two-path unifying theory of hemostasis’: philosophical, physiological, and phenotypical interpretation. Blood Coagul Fibrinolysis. 2018;29:585–595.
- Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19:287.
- Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med. 2020;15:1375–1387.
- Zhang C, Zhang Z, Mi J, et al. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine (Baltimore). 2019;98:e15833.
- Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest. 2003;124(6 Suppl):357S–363S.
- Hamada SR, Espina C, Guedj T, et al. High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol. Ann Intensive Care. 2017;7:97.
- Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33:2156–2168.
- Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135–1140.
- Valdivia-Mazeyra MF, Salas C, Nieves-Alonso JM, et al. Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature. Virchows Arch. 2020;1–10.
- Thachil J, Lisman T. Pulmonary Megakaryocytes in Coronavirus Disease 2019 (COVID-19): roles in thrombi and fibrosis. Semin Thromb Hemost. 2020;46:831–834.
- Palumbo D, Guazzarotti G, De Cobelli F. Spontaneous major hemorrhage in COVID-19 patients: another brick in the wall of SARS-CoV-2-associated coagulation disorders? J Vasc Interv Radiol. 2020;31:1494–1496.
- Hardy M, Lecompte T, Douxfils J, et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis J. 2020;18:17.
- Tsutsumi T, Saito M, Nagai H, et al. Association of coagulopathy with liver dysfunction in patients with COVID-19. Hepatol Res. 2021;51:227–232.
- Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9:687–690.
- Qian SZ, Pan JY. COVID-19 with limb ischemic necrosis. J Cardiothorac Vascul Anesth COVID-19. 2020;34:2846–2847.
- Suarez-Valle A, Fernandez-Nieto D, Diaz-Guimaraens B, et al. Acro-ischaemia in hospitalized COVID-19 patients. J Eur Acad Dermatol Venereol. 2020;34:e455–e457.
- Khan IA, Karmakar S, Chakraborty U, et al. Purpura fulminans as the presenting manifestation of COVID-19. Postgrad Med J. 2021.
- Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol. 2020;183:431–442.
- Novara E, Molinaro E, Benedetti I, et al. Severe acute dried gangrene in COVID-19 infection: a case report. Eur Rev Med Pharmacol Sci. 2020;24(10):5769–5771.
- Del Giudice P, Boudoumi D, Le Guen B, et al. Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy. J Eur Acad Dermatol Venereol. 2020;34(11):e679–e680.
- Chang JC, Ikhlaque N. Peripheral digit ischemic syndrome can be a manifestation of postoperative thrombotic thrombocytopenic purpura. Ther Apher Dial. 2004;8:413–418.
- Warkentin TE. Microvascular thrombosis and ischaemic limb losses in critically Ill patients. Hamostaseologie. 2019;39:6–19.
- Shimbo K, Yokota K, Miyamoto J, et al. Symmetrical peripheral gangrene caused by septic shock. Case Rep Plast Surg Hand Surg. 2015;2:53–56.
- Davis MD, Dy KM, Nelson S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. J Am Acad Dermatol. 2007;57:944–956.
- Kox M, Waalders NJB, Kooistra EJ, et al. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020;324:1565–1567.
- Martinelli N, Montagnana M, Pizzolo F, et al. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thrombo Res. 2020;193:170–172.
- Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19:513–521.
- Fogarty H, Townsend L, Cheallaigh CN, et al. COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189:1044–1049.
- McGonagle D, O’Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2:e437–45.
- Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38.
- Marchandot B, Sattler L, Jesel L, et al. COVID-19 related coagulopathy: a distinct entity? J Clin Med. 2020;9:E1651.
- Becker RC. COVID-19 update: covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54–67.
- Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–e440.
- Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.
- Sridharan M, Ashrani A, Chen D. et al. Evaluation of soluble fibrin monomer complex in patients with Sars-Cov-2 COVID-19. Infection Blood. 2020;136(Supplement 1):27–28.
- Ladikou EE, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond). 2020;20:e178–e182.
- Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46:1603–1606.
- Cipolloni L, Sessa F, Bertozzi G, et al. Preliminary Post-Mortem COVID-19 evidence of endothelial injury and factor VIII hyperexpression. Diagnostics (Basel). 2020;10:575.
- Rauch A, Labreuche J, Lassalle F, et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost. 2020;18:2942–2953.
- Huisman A, Beun R, Sikma M, et al. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020;42:e211–e212.
- Bazzan M, Montaruli B, Sciascia S, et al. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med. 2020;15:861–863.
- Madeeva DV, Christian J, Goshua G, et al. VWF/ADAMTS13 ratios are potential markers of immunothrombotic complications in patients with COVID-19: a cross-sectional study. Blood. 2020;136(Supplement 1):34–35.
- Chang JC. Hemostasis based on a novel ‘two-path unifying theory’ and classification of hemostatic disorders. Blood Coagul Fibrinolysis. 2018;29:573–584.
- Turner NA, Moake JL. Factor VIII is synthesized in human endothelial cells, packaged in Weibel-Palade bodies and secreted bound to ULVWF strings. PLoS One. 2015;10:e0140740.
- Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91(1):1–19.
- De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121:270–277.
- Mourik MJ, Valentijn JA, Voorberg J, et al. von Willebrand factor remodeling during exocytosis from vascular endothelial cells. J Thromb Haemost. 2013;11:2009–2019.
- Huang J, Roth R, Heuser JE, et al. Integrin αvβ3 on human endothelialcells binds von Willebrand factor strings under fluid shear stress. Blood. 2009;113:1589–1597.
- Chauhan AK, Goerge T, Schneider SW, et al. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007;5:583–589.
- Chen X, Cheng X, Zhang S, et al. ADAMTS13: an emerging target in stroke therapy. Front Neurol. 2019;10:772.
- Sonneveld MA, de Maat MP, Portegies ML, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126:2739–2746.
- Denorme F, Kraft P, Pareyn I, et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017;12:e0179258.
- Eerenberg ES, Teunissen PF, van den Born BJ, et al. The role of ADAMTS13 in acute myocardial infarction: cause or consequence? Cardiovasc Res. 2016;111:194–203.
- Horii M, Uemura S, Uemura M, et al. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels. 2008;23:301–307.
- Pagliari MT, Boscarino M, Cairo A, et al. ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thromb Res. 2021;197:132–137.
- Zhao J, Yang Y, Huang H, et al. Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) Susceptibility. Clin Infect Dis. 2020;ciaa1150.
- Wu Y, Feng Z, Li P, et al. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta. 2020;509:220–223.
- Li J, Wang X, Chen J, et al. Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia. Br J Haematol. 2020;2020(190):24–27.
- Gaffney PJ. Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta. 1975;65:109–115.
- Shorr AF, Thomas SJ, Alkins SA, et al. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest. 2002;121:1262–1268.
- Goebel PJ, Williams JB, Gerhardt RT. A pilot study of the performance characteristics of the D-dimer in presumed sepsis. West J Emerg Med. 2010;11:173–179.
- Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149.
- Maldonado E, Tao D, Mackey K. Antithrombotic therapies in COVID-19 disease: a systematic review. J Gen Intern Med. 2020;17:1–9.
- Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18:1752–1755.
- Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30.
- Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–2344.
- FitzGerald GA. Misguided drug advice for COVID-19. Science. 2020;367(6485):1434.
- Rizk JG, Kalantar-Zadeh K, Mehra M, et al. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020;80:1267–1292.
- Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119:6128–6135.
- Azfar MF, Khan MF, Habib SS, et al. Prognostic value of ADAMTS13 in patients with severe sepsis and septic shock. Clin Invest Med. 2017;40:E49–E58.
- Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost. 2018;16:646–651.
- Peetermans M, Meyers S, Liesenborghs L, et al. Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis. J Thromb Haemost. 2020;18:722–731.
- Khamis F, Al-Zakwani I, Al Hashmi S, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214–218.
- Dogan L, Kaya D, Sarikaya T, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun. 2020;87:155–158.
- Faqihi F, Alharthy, A, Alodat, Met al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Trials. 2020;21:506.
- Keith P, Day M, Choe C, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE Open Med Case Rep. 2020;8:2050313X20933473.
- Shi H, Zhou C, He P, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents. 2020;56:105974.
- Adeli SH, Asghari A, Tabarraii R, et al. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series. Pol Arch Intern Med. 2020;130:455–458.
- Valga F, Vega- Díaz N, Macia M, et al. Targeting complement in severe Coronavirus disease 2019 to address microthrombosis. Clin Kidney J. 2020;13:477–479.
- Stahel PF, Barnum SR. Complement inhibition in coronavirus disease (COVID)-19: a neglected therapeutic option. Front Immunol. 2020;11:1661.
- Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine. 2020;28:100590.
- Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24:4040‐4047.
- Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450.
- Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? JCI Insight. 2020;5:e140711.
- Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593–603.
- Dong Z, Thoma RS, Crimmins DL, et al. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem. 1994;269:6753–6758.
- Yeh HC, Zhou Z, Choi H, et al. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost. 2010;8:2778–2788.
- Aldini G, Altomare A, Baron G, et al. N-acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52:751–762.
- Samuni Y, Goldstein S, Dean OM, et al. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830:4117–4129.
- Cabanillas G, Popescu-Martinez A. N-acetylcysteine for relapsing thrombotic thrombocytopenic purpura: more evidence of a promising drug. Am J Ther. 2016;23:e1277–1279.
- Rottenstreich A, Hochberg-Klein S, Rund D, et al. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016;41:678–683.
- Tersteeg C, Roodt J, Van Rensburg WJ, et al. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood. 2017;129:1030–1038.
- Suter PM, Domenighetti G, Schaller MD, et al. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190–194.
- Domenighetti G, Suter PM, Schaller MD, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12:177–182.
- Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164–172.
- Moradi M, Mojtahedzadeh M, Mandegari A, et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med. 2009;103:434–441.
- Zhang Y, Ding S, Li C, et al. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2017;14:2863–2868.
- Divatia JV, Khan PU, Myatra SN. Tracheal intubation in the ICU: life-saving or life threatening? Indian J Anaesth. 2011;55:470–475.
- Spieth PM, de Abreu MG. Pulmonary embolism in mechanically ventilated patients: what the eye doesn’t see, the heart can still grieve over. Crit Care Med. 2012;40:3320–3321.
- Guglielmetti G, Quaglia M, Sainaghi PP, et al. “War to the knife” against thromboinflammation to protect endothelial function of COVID-19 patients. Crit Care. 2020;24:365.
- Shi Z, Puyo CA. N-Acetylcysteine to Combat COVID-19: an evidence review. Ther Clin Risk Manag. 2020;16:1047–1055.